Anthony Tolcher is an Oncology physician. ClinicalTrials.gov lists 18 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2829 Babcock Rd Ste 300
San Antonio, TX 782296011
Telephone
210-580-9500Provider last certified this registry record 12 Mar 2021.
Clinical trials
- PTX-35 in Patients With Advanced Solid Tumors
Sponsor: Pelican Therapeutics, Inc.
- A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
Sponsor: NatureWise Biotech & Medicals Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
59 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Healthcare KGaAProgram year20255 payments$16,841openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year20251 payment$11,536openpaymentsdata.cms.gov ↗
- EMD Serono Research & Development Institute, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
56.5%RANK Ligand Inhibitor56.5%Denosumab100%Part B, office-administered≥18 patientsBlood & clotting
36.9%Parenteral Iron Replacement36.7%Iron sucrose100%Part B, office-administered≥11 patientsFactor Xa inhibitor0.2%Eliquis65%Xarelto36%Part D<11 patientsSensory organs
3.4%Corticosteroid3.4%Dexamethasone sodium phosphate98%Hydrocortisone3%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1999–2007 per NIH RePORTER. The latest:
- PH I STUDY OF EGFR AND HER2 BLOCKADE W/ OSI-774, TRASTUZUMAB AND PACLITAXEL
University of Texas Hlth Science Center
FY2007$12,053M01RR001346 - Phase I Clinical Trials of Anti-Cancer Agents
Cancer Therapy and Research Center
FY2006$497,588U01CA069853 - PH I STUDY OF EGFR AND HER2 BLOCKADE W/ OSI-774, TRASTUZUMAB AND PACLITAXEL
University of Texas Hlth Science Center
FY2006$23,191M01RR001346
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”